Are there any risks associated with long-term use of giritinib/segatan?

Gilitinib/Segatan (Gilteritinib), as an innovative oral inhibitor targeting FLT3 mutations, has played an important role in the treatment of acute myeloid leukemia (AML) since its approval. Since AML is a malignant hematological tumor with a high recurrence rate, many patients require long-term or continuous treatment, which raises a core question: whether long-term use of gilitinib will bring greater risks.

According to clinical experience, the long-term use of giritinib mainly involves risks at several levels: First, common drug-related side effects may accumulate over time, including fatigue, nausea, decreased appetite, and increased liver function indicators. These symptoms can usually be alleviated through supportive care, dietary changes, or symptomatic treatment, but they require long-term monitoring to avoid being ignored.

Second, some patients may experience serious adverse reactions, such as differentiation syndrome, abnormal heart rhythm or blood pressure fluctuations. Although the incidence rate of this type of reaction is not extremely high, once it occurs, it may affect the prognosis. Therefore, doctors usually require patients to perform regular electrocardiograms, blood routine tests, and liver and kidney function tests during long-term medication.

The third is the risk of drug resistance. As the treatment time is prolonged, some AML patients may have new genetic mutations in tumor cells that may reduce their sensitivity to giritinib. This is also an important reason why long-term treatment requires comprehensive evaluation.

In general, international research reports show that the risks of long-term use of gilitinib are controllable. Reasonable monitoring and dosage adjustment under the guidance of doctors can maximize the benefit to patients. Therefore, geritinib is still one of the widely recommended first-line options for AML patients who require long-term maintenance treatment.

Reference materials:https://www.xospata.com/